Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:0
作者
Fukuda, Tatsuya [1 ,2 ,3 ,4 ]
Akihisa, Taro [2 ,4 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro
Kawakami, Akio [4 ]
Tanaka, Makoto [5 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [4 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo 1600022, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, 2-44-1 Kabuki-cho,Shinjyuku ku, Tokyo 1608488, Japan
[3] Inst Sci Tokyo, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo 1138510, Japan
[4] Shinjuku Tsurukame Clin, Tokyo 1510053, Japan
[5] Koganei Tsurukame Clin, Tokyo 1840004, Japan
关键词
Metabolic dysfunction-associated steatotic liver disease (MASLD); Nonalcoholic fatty liver disease (NAFLD); Metabolic and alcohol related/associated liver disease (MetALD); Alcohol consumption; Uric acid; INSULIN-RESISTANCE; HYPERURICEMIA; INDEX; RISK;
D O I
10.1507/endocrj.EJ24-0622
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hyperuricemia reflects increased insulin resistance, and uric acid (UA) may serve as a predictive marker for the development of metabolic dysfunction-associated steatotic liver disease (MASLD); however, few studies have investigated this condition in the Japanese population. Thus, this retrospective observational study aimed to investigate the association of hyperuricemia with the risk of MASLD or metabolic and alcohol-related liver disease (MetALD) in individuals undergoing health checkups. A cross-sectional analysis was performed on 58,110 individuals, dividing them into quartile groups according to UA values for men and women (Q1 being the lowest and Q4 being the highest), and examining the complication rate of MASLD/MetALD. Subsequently, among 22,364 individuals without MASLD/MetALD, the relationship between UA at baseline and MASLD/MetALD development during follow-up was investigated using Cox proportional hazard models. In the cross-sectional analysis, the higher UA group had a higher complication rate of MASLD/MetALD in both men and women. In the follow-up analysis, both genders in the higher UA quartiles had a significantly higher incidence of MASLD/ MetALD than those in the lower quartiles. Multivariate Cox proportional hazards analysis revealed that Q4 had a significantly higher hazard ratio than Q1 for both genders. These trends were the same in the time-dependent body mass index (BMI) model, which incorporated BMI as a time-dependent variable. High UA levels may serve as a predictive marker for MASLD/ MetALD development. UA monitoring during health checkups could enable early detection and provision of intervention, improving patient outcomes.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Association between serum per- and polyfluoroalkyl substances levels and metabolic dysfunction-associated steatotic liver disease
    Zhang, Jin
    Cheng, Xu
    Wang, Yu
    Guo, Hong
    Liu, Lin
    Liu, Lu
    Gao, Junya
    He, Meian
    ENVIRONMENTAL POLLUTION, 2024, 363
  • [32] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [33] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [34] Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Chronic Periodontitis: A Nationwide Cohort Study
    Shine, Bo-Kyung
    Son, Minkook
    Moon, Sang Yi
    Han, Seong-Ho
    NUTRIENTS, 2025, 17 (01)
  • [35] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [36] Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography
    Kim, Myung Jin
    Cho, Yun Kyung
    Kim, Eun Hee
    Lee, Min Jung
    Lee, Woo Je
    Kim, Hong-Kyu
    Jung, Chang Hee
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (05) : 1942 - 1952
  • [37] Association of antinuclear antibody positivity with liver disease severity in pediatric metabolic dysfunction-associated steatotic liver disease
    Kim, Hyun Jin
    Kim, Ju Young
    Lee, Yoo Min
    Hong, Yong Hee
    Kang, Ben
    Choe, Byung-Ho
    Yi, Dae Yong
    Lee, Eun Hye
    Kim, Soon Chul
    Choi, You Jin
    Jang, Hyo-Jeong
    Choi, So Yoon
    FRONTIERS IN PEDIATRICS, 2025, 13
  • [38] Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Oh, Juyeon
    Kim, Beom Kyung
    Yoon, Jin-Ha
    Lee, Hyung Ho
    Park, Heejoo
    Lee, Jian
    Park, Youngsun
    Yun, Byungyoon
    Chung, Jinsoo
    CANCERS, 2024, 16 (18)
  • [39] Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Sei, Motoko
    Kagemoto, Kaizo
    Tanaka, Hironori
    Kida, Yoshifumi
    Nakamura, Fumika
    Tomonari, Tetsu
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (04) : 754 - 761
  • [40] Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay
    Arvanitakis, Konstantinos
    Chatzikalil, Elena
    Kalopitas, Georgios
    Patoulias, Dimitrios
    Popovic, Djordje S.
    Metallidis, Symeon
    Kotsa, Kalliopi
    Germanidis, Georgios
    Koufakis, Theocharis
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)